NSE filing, NSE: CURIS. Summary written from the filing by ALFA Finder's alert engine.
Curis Lifesciences Ltd: key numbers
- Share price
- ₹181.50
- Market cap
- ₹146.7 Cr
- Revenue (annual)
- ₹60.63 Cr
- Net profit (annual)
- ₹6.92 Cr
- P/E (TTM)
- 21.2×Sector 46.1×
- Promoter holding
- 68.03%
- FII holding
- 1.05%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Curis Lifesciences Ltd
All →Curis Lifesciences Other Announcement
Curis Lifesciences Limited informed that it is not required to submit a Corporate Governance Report, as its securities are listed on the SME platform.
Curis Lifesciences Annual General Meeting
Curis Lifesciences Limited conducted its 10th Annual General Meeting on September 29, 2026, to transact various agenda items, including financial statement adoption and director appointments.
Curis Lifesciences Annual General Meeting
Curis Lifesciences filed its 10th AGM notice and FY 2025-26 Annual Report. The meeting is scheduled for September 29, 2026.
Curis Lifesciences Board Meeting Outcome
Curis Lifesciences Limited approved the Director's Report, related party transactions, and scheduled its 10th Annual General Meeting for September 29, 2026. Board outcomes were finalized.
Curis Lifesciences Management Change
Curis Lifesciences Limited announced the resignation of Mr. Nikhil Purohit as Company Secretary and Compliance Officer, effective September 3, 2026.
Curis Lifesciences Merger & Restructuring Worth ₹0.05 Cr
Curis Lifesciences Limited has acquired a 49.95% stake in CUROSUN PHARMACEUTICAL NIG LTD, Nigeria, for Rs. 5 Lakhs to expand its pharmaceutical market presence.
- Value
- ₹0.05 Cr
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.